×
To start your customized experience click the start button
Customize ?  
Start
Cancer Types
Quick Links
Events
Award Programs
About Us
Careers
Contact Us
Newsroom
Privacy Policy
Terms & Conditions
 
Twitter
Face Book
YouTube
Instagram
 
 
Cure Media Group, LLC.
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
P: 800-210-2873

Copyright © 2019
CURE Media Group.
All rights reserved.
Cure Media Group, LLC. All Rights Reserved.
CURE does not provide medical, diagnostic, or treatment advice.

Metastatic Breast Cancer

Tammy Summers
One person with cancer details their challenges with fighting for social security while battling a metastatic breast cancer diagnosis.
Martha Carlson
It's not just time spent sitting in the lobby. Waiting is a way of life for people with cancer.
Kathy LaTour
Cancer changes us, and often we find new parts of ourselves that help us accomplish new goals in the face of adversity and tragedy.
 
Ryan McDonald
The Food and Drug Administration’s recent approval of the first antibody-drug conjugate to treat patients with pretreated metastatic triple-negative breast cancer is a major milestone, according to one expert.
 
Beth Fand Incollingo and Kristi Rosa
The Food and Drug Administration approved the targeted therapy Tukysa as part of a drug combination to treat HER2-positive breast cancer. Here’s what you need to know.
 
Melissa K. Accordino, MD, MS
Looking at new data from the phase 3 PEARL trial, Dr. Melissa K. Accordino discusses how the use of CDK4/6 inhibitors could help patients with HR-positive/HER2-negative metastatic breast cancer move away from chemotherapy.
 
Jessica Skarzynski
In this week’s episode of the “CURE Talks Cancer Podcast” Melissa Surdez discusses her journey with metastatic breast cancer through the COVID-19 Pandemic.
 
Martha Carlson
Choosing the best path forward is hard under any circumstance, but today, those decisions are wrought with additional unknowable risks.
Martha Carlson
Survival strategies for her best life help this metastatic cancer patient navigate a new world in the wake of the COVID-19 pandemic. 
Ryan McDonald
The Food and Drug Administration approved an updated dose of Ontruzant, a biosimilar to Herceptin, for multiple cancer types.
×
×

Sign In

Not a member? Sign up now!
Continue without login
Continue
×